Analyzing Pathfinder Cell Therapy (OTCMKTS:PFND) and Nutriband (NASDAQ:NTRB)

Pathfinder Cell Therapy (OTCMKTS:PFND) and Nutriband (NASDAQ:NTRB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Pathfinder Cell Therapy and Nutriband, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pathfinder Cell Therapy	0	0	0	0	0.00
Nutriband	0	0	1	0	3.00

Nutriband has a consensus target price of $13.00, suggesting a potential upside of 107.67%. Given Nutriband’s stronger consensus rating and higher possible upside, analysts clearly believe Nutriband is more favorable than Pathfinder Cell Therapy.

Earnings and Valuation

This table compares Pathfinder Cell Therapy and Nutriband”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A
Nutriband	$2.02 million	34.39	-$5.49 million	($0.71)	-8.82

Pathfinder Cell Therapy has higher earnings, but lower revenue than Nutriband.

Institutional and Insider Ownership

19.7% of Nutriband shares are held by institutional investors. 15.1% of Pathfinder Cell Therapy shares are held by company insiders. Comparatively, 54.1% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Pathfinder Cell Therapy and Nutriband’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pathfinder Cell Therapy	N/A	N/A	N/A
Nutriband	-338.51%	-54.49%	-48.52%

Summary

Nutriband beats Pathfinder Cell Therapy on 6 of the 9 factors compared between the two stocks.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.